Case Report
Published on 13 Nov 2024
When multiple primary lung cancers express the same rare mutation: a case report
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1475193
- 1,359 views
- Frontiers in Oncology
- Thoracic Oncology
- Articles
Type at least 3 characters
1,913 articles
articles
Original Research
Published on 08 Nov 2024
Development and validation of a nomogram for predicting histologic subtypes of subpleural non-small cell lung cancer using ultrasound parameters and clinical data
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1477450
- 1,327 views
Review
Published on 08 Nov 2024
Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1447678
- 4,348 views
- 7 citations
Systematic Review
Published on 07 Nov 2024
Efficacy and safety of Toliparibumab for the treatment of non-small cell lung cancer: a systematic review and meta-analysis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1444312
- 2,492 views
- 1 citation
Case Report
Published on 07 Nov 2024
Case report: Pulmonary Ewing sarcoma disguised as non-small cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1449119
- 2,717 views
Case Report
Published on 07 Nov 2024
Case report: Combination therapy of envafolimab with endostar for advanced non-small cell lung cancer with low PD-L1 expression
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1437260
- 1,796 views
- 2 citations
Original Research
Published on 04 Nov 2024
The causal nexus between diverse smoking statuses, potential therapeutic targets, and NSCLC: insights from Mendelian randomization and mediation analysis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1438851
- 2,356 views
- 2 citations
Editorial
Published on 04 Nov 2024
Editorial: Innovative strategies and new insights for the treatment of stage III non-small cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1503613
- 1,174 views
Original Research
Published on 04 Nov 2024
Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational study
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1400277
- 2,554 views
Mini Review
Published on 01 Nov 2024
Exercise’s impact on lung cancer molecular mechanisms: a current overview
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1479454
- 3,263 views
- 1 citation
Case Report
Published on 01 Nov 2024
Therapeutic strategies to overcome ALK-fusion and BRAF-mutation as acquired resistance mechanism in EGFR-mutated non-small cell lung cancer: two case reports
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1390523
- 2,284 views
- 1 citation
Editorial
Published on 31 Oct 2024
Editorial: Advances in the use of EGFR TKIs in the treatment of NSCLC
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1506160
- 1,400 views
Case Report
Published on 31 Oct 2024
Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer—a case series of divergent results from a large reference laboratory
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1445668
- 2,366 views
Original Research
Published on 30 Oct 2024
The value of multiple diffusion metrics based on whole-lesion histogram analysis in evaluating the subtypes and proliferation status of non-small cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1434326
- 1,708 views
- 3 citations
Case Report
Published on 29 Oct 2024
Primary hepatoid adenocarcinoma of the lung in patient with silicosis: a case report and literature review
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1380717
- 1,721 views
Review
Published on 29 Oct 2024
Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1411432
- 6,531 views
- 4 citations
Correction
Published on 28 Oct 2024
Corrigendum: Prognostic significance of FDG PET/CT in esophageal squamous cell carcinoma in the era of the 8th AJCC/UICC staging system
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1505996
- 1,040 views
Systematic Review
Published on 25 Oct 2024
Worldwide research trends on bone metastases of lung cancer: a bibliometric analysis
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1429194
- 2,694 views
- 2 citations
Original Research
Published on 25 Oct 2024
Real-world treatment patterns, biomarker testing, and clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1442909
- 2,913 views
- 1 citation
Original Research
Published on 24 Oct 2024
Machine learning-based prediction of 5-year survival in elderly NSCLC patients using oxidative stress markers
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1482374
- 2,113 views
- 1 citation
Review
Published on 22 Oct 2024
Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1449490
- 2,798 views
- 3 citations
Original Research
Published on 21 Oct 2024
A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1422035
- 3,519 views
- 3 citations
Original Research
Published on 21 Oct 2024
The potential role of next-generation sequencing in identifying MET amplification and disclosing resistance mechanisms in NSCLC patients with osimertinib resistance
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1470827
- 3,177 views
- 2 citations
Systematic Review
Published on 21 Oct 2024
The benefit and risk of addition of chemotherapy to EGFR tyrosine kinase inhibitors for EGFR-positive non-small cell lung cancer patients with brain metastases: a meta-analysis based on randomized controlled trials
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1448336
- 2,555 views